Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 9/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150978 | 0.79 | GRIN2D (0.45) | HRH3DHFRGPR119 | |
| SCHEMBL26048795 | 0.78 | HRH3 (0.44) | HRH3HCRTR1HCRTR2DHFRACACB | |
| SCHEMBL10121068 | 0.78 | ACACB (0.49) | ACACB | |
| SCHEMBL9366521 | 0.75 | HRH3 (0.65) | HRH3MEN1KMT2ADHFR | |
| SCHEMBL14650779 | 0.75 | UBE2T (0.51) | HRH3MEN1KMT2ADHFR | |
| Hydrochloric Acid SCHEMBL29086063 | 0.74 | HRH3 (0.46) | HRH3HCRTR1HCRTR2KMT2ADHFR | |
| Hydrochloric Acid SCHEMBL30585985 | 0.74 | HRH3 (0.46) | HRH3HCRTR1HCRTR2KMT2ADHFR | |
| SCHEMBL27837554 | 0.73 | UBE2T (0.50) | HRH3MEN1KMT2ADHFR | |
| SCHEMBL3920532 | 0.72 | DHFR (0.48) | HRH3MEN1KMT2ADHFR | |
| SCHEMBL30790747 | 0.72 | HRH3 (0.53) | HRH3MEN1KMT2ADHFRGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HRH3 4540/4885HCRTR1 4007/4885HCRTR2 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.